LaFleur & Godfrey LLC Decreases Stock Holdings in AbbVie Inc. $ABBV

LaFleur & Godfrey LLC lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 3.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 75,562 shares of the company’s stock after selling 2,975 shares during the quarter. AbbVie comprises 2.1% of LaFleur & Godfrey LLC’s portfolio, making the stock its 14th largest holding. LaFleur & Godfrey LLC’s holdings in AbbVie were worth $17,496,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Payden & Rygel increased its holdings in shares of AbbVie by 52,090.9% in the 3rd quarter. Payden & Rygel now owns 57,410 shares of the company’s stock worth $13,293,000 after buying an additional 57,300 shares during the last quarter. Clearstead Trust LLC lifted its holdings in shares of AbbVie by 0.6% in the 3rd quarter. Clearstead Trust LLC now owns 14,657 shares of the company’s stock valued at $3,394,000 after acquiring an additional 81 shares during the last quarter. X Square Capital LLC grew its position in AbbVie by 1.6% in the third quarter. X Square Capital LLC now owns 15,929 shares of the company’s stock worth $3,688,000 after acquiring an additional 255 shares in the last quarter. Avalon Trust Co increased its stake in AbbVie by 5.6% during the third quarter. Avalon Trust Co now owns 3,456 shares of the company’s stock worth $800,000 after acquiring an additional 184 shares during the last quarter. Finally, Quantum Private Wealth LLC increased its stake in AbbVie by 7.6% during the third quarter. Quantum Private Wealth LLC now owns 2,330 shares of the company’s stock worth $539,000 after acquiring an additional 164 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.3%

Shares of AbbVie stock opened at $224.94 on Monday. The stock’s fifty day moving average is $224.04 and its two-hundred day moving average is $222.24. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81. The company has a market capitalization of $397.56 billion, a PE ratio of 95.31, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ABBV shares. UBS Group lowered their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. Barclays assumed coverage on AbbVie in a research report on Thursday. They issued an “overweight” rating and a $275.00 price target for the company. Morgan Stanley lifted their price objective on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Piper Sandler boosted their price objective on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Evercore lowered their target price on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $252.79.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA approved the VENCLEXTA® (venetoclax) + acalabrutinib combination for previously untreated chronic lymphocytic leukemia (CLL). This is the first all‑oral, fixed‑duration combo for this setting, supported by Phase 3 AMPLIFY data—it can meaningfully expand uptake for Venclexta and acalabrutinib, strengthen AbbVie’s oncology franchise and offer a durable revenue stream versus one‑off treatments. U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
• Positive Sentiment: Industry write‑ups frame the FDA approval as a potential new standard for a slow‑growing blood cancer, highlighting better three‑year outcomes and the “time off therapy” selling point—this can accelerate physician adoption and market share vs. chemo regimens. FDA Approval For AbbVie/AstraZeneca’s Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
• Positive Sentiment: AbbVie opened a Phase 2a study for ABBV‑142 in idiopathic pulmonary fibrosis (IPF), broadening its respiratory/pulmonary pipeline beyond core immunology and oncology programs. Early‑stage pipeline depth helps investor sentiment around post‑Humira growth optionality. AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142
• Positive Sentiment: Board declared a $1.73 quarterly dividend (yield ~3.1%), reinforcing the income profile for dividend‑focused investors and supporting the stock’s defensive appeal. Dividend cadence and yield matter for total return expectations. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: Quarterly results and commentary show Rinvoq and Skyrizi continuing to drive top‑line growth and offset Humira erosion; that underpins management’s guidance but much of these dynamics are already reflected in recent estimates. Will Immunology Drugs Continue to Drive AbbVie’s Top Line in 2026?
• Neutral Sentiment: Coverage pieces ask whether AbbVie’s post‑Humira pipeline merits renewed investor attention — useful for narrative, but these are discussion pieces rather than new data that would immediately re‑rate the stock. Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?
• Neutral Sentiment: Marketing/PR items (new podcast, inclusion in dividend lists, media mentions) help brand and investor awareness but are unlikely to move fundamentals in the near term. AbbVie heads to ‘The Persistence Lab’ in new podcast highlighting healthcare innovation
• Negative Sentiment: Evercore noted Tremfya’s share gains but flagged possible limits to future earnings growth and trimmed its price target slightly—this is a modest analyst headwind that could cap upside if more firms follow with tepid updates. Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.